These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10721684)

  • 1. Use of slow-release melatonin in treatment-resistant depression.
    Dalton EJ; Rotondi D; Levitan RD; Kennedy SH; Brown GM
    J Psychiatry Neurosci; 2000 Jan; 25(1):48-52. PubMed ID: 10721684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
    Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
    J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation.
    Licht RW; Qvitzau S
    Psychopharmacology (Berl); 2002 May; 161(2):143-51. PubMed ID: 11981594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metyrapone as additive treatment in major depression: a double-blind and placebo-controlled trial.
    Jahn H; Schick M; Kiefer F; Kellner M; Yassouridis A; Wiedemann K
    Arch Gen Psychiatry; 2004 Dec; 61(12):1235-44. PubMed ID: 15583115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.
    Baune BT; Caliskan S; Todder D
    Hum Psychopharmacol; 2007 Jan; 22(1):1-9. PubMed ID: 17191266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders.
    Lee MS; Lee HY; Kang SG; Yang J; Ahn H; Rhee M; Ko YH; Joe SH; Jung IK; Kim SH
    J Affect Disord; 2010 Jun; 123(1-3):216-21. PubMed ID: 19914719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
    Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
    J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.
    Serfaty MA; Osborne D; Buszewicz MJ; Blizard R; Raven PW
    Int Clin Psychopharmacol; 2010 May; 25(3):132-42. PubMed ID: 20195158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression.
    Schmidt PJ; Daly RC; Bloch M; Smith MJ; Danaceau MA; St Clair LS; Murphy JH; Haq N; Rubinow DR
    Arch Gen Psychiatry; 2005 Feb; 62(2):154-62. PubMed ID: 15699292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients.
    Feighner JP; Sverdlov L; Hlavka J; Nicolau G; Cartwright K; Freed JS
    Int Clin Psychopharmacol; 2008 Jan; 23(1):29-35. PubMed ID: 18090505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium.
    Dorée JP; Des Rosiers J; Lew V; Gendron A; Elie R; Stip E; Tourjman SV
    Curr Med Res Opin; 2007 Feb; 23(2):333-41. PubMed ID: 17288688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder.
    Dunner DL; Wilson M; Fava M; Kornstein S; Munoz R; O'Reardon J; Trivedi M; Wohlreich M
    Depress Anxiety; 2008; 25(5):E1-8. PubMed ID: 17621644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression.
    Liebrenz M; Stohler R; Borgeat A
    World J Biol Psychiatry; 2009; 10(4 Pt 2):640-3. PubMed ID: 17853274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled trial of duloxetine alone vs. duloxetine plus a telephone intervention in the treatment of depression.
    Perahia DG; Quail D; Gandhi P; Walker DJ; Peveler RC
    J Affect Disord; 2008 May; 108(1-2):33-41. PubMed ID: 17905442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.